Abstract
In November 2025, a traveler from Cuba tested positive for chikungunya virus upon arrival to Mexico. The virus belonged to the East-Central-South-African lineage, clustering with a clade prevalent in Brazil. Ten years after the last chikungunya epidemic in Mexico, strengthened surveillance is required to anticipate transmission of this emergent lineage.
- Chikungunya virus
- phylogenetics
- arbovirus
- Mexico
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the Wellcome Trust Infectious 155 Disease Award (317324/Z/24/Z). MGK is funded through a Sanger International Fellowship award. MEZ is funded by a UCL Rosetrees Excellence Fellowship UCL2024\2.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The ethics committee of the Universidad Autonoma de Yucatan (UADY) in Merida, Mexico waived the ethical approval for this work based on the regulations applicable in Mexico, such as the General Health Law and the Official Mexican Standard NOM-27 012-SSA3-2012 on health research. which focuses on presenting laboratory results from a specific case as a descriptive analysis, which did not involve invasive procedures or significant risks to the patient.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵2 Additional members of the ARCC Research Consortium are listed at the end of this article
Additional members of the ARCC Research Consortium: Julius Lutwama and John Kayiwa (UVRI, Uganda), (UVRI, Uganda), Tierra Smiley and David J Wolking (UC Berkeley, USA) and Benard Sebidde (Gorilla Doctors, Uganda).
Data Availability
All data produced in the present work are contained in the manuscript.
